Adaptive Biotechnologies Corp. (ADPT)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Adaptive Biotechnologies Corp. (ADPT)
Go deeper and ask any question about ADPT
Company Performance
Current Price
as of Sep 13, 2024$4.61
P/E Ratio
N/A
Market Cap
$679.85M
Description
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
Metrics
Overview
- HQSeattle, WA
- SectorHealth Technology
- IndustryBiotechnology
- TickerADPT
- Price$4.61+7.21%
Trading Information
- Market Cap$679.85M
- Float96.52%
- Average Daily Volume (1m)884,965
- Average Daily Volume (3m)1,328,015
- EPS-$1.47
Company
- Revenue$168.77M
- Rev Growth (1yr)-11.72%
- Net Income-$46.22M
- Gross Margin48.83%
- EBITDA Margin-79.72%
- EBITDA-$34.43M
- EV$467.84M
- EV/Revenue2.77
- P/EN/A
- P/S4.03
Documents
SEC Filings
Factset Street Account